Vol 52 No 04

"I am still struggling with disposing the scopes after each use, both from the environmental aspect and the fact that the scope technically can be used more than once," writes Gopal H. Badlani, MD.

“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.

“This research suggests that proactive and continuous management of metabolic syndrome may serve as an essential strategy in preventing cancer," says Han-Ping Shi, MD, PhD.

“The impact of precision medicine in prostate cancer has been significant over a relatively brief period,” says Leonard G. Gomella, MD, FACS.

"[Now that] we have entered the era of precision and personalized medicine, well-designed clinical trials are needed to address selected focused questions regarding optimal therapy sequencing,” says Maha H.A. Hussain, MBChB.

In this interview, Joshua Langston, MD, highlights a session on Medicare reimbursement reform from the 7th Annual AUA Urology Advocacy Summit.

In this interview, Robert Reiter, MD, MBA, discusses the accuracy of PSMA-PET scans, false negative and false positive rates, and how treatment with ADT affects PSMA uptake.

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

The safety and efficacy of BXCL701 in combination with pembrolizumab is currently under investigation in a phase 2 trial.

"This work and previous work supports the idea that EBV not only causes MS, but also continues to affect disease progression," write the authors.